

- Cancer genetics (*Cont.*):  
 CpG islands in, 430, 431  
 cytogenetic analysis in, 83e-7  
 DNA methylation in, 431  
 epigenetic control mechanisms, 101e-4  
 epigenetic influences on gene transcription, 102e-7-8, 102e-8f  
 familial cancer syndromes, 101e-6-7, 101e-6t, 101e-8f  
 future of, 101e-9  
 gene expression and, 101e-7, 101e-8f  
 genomewide mutational profiling, 101e-7-8, 101e-9f  
 historical perspective, 101e-1  
 microRNAs in, 101e-7  
 somatic mutations in, 440  
 treatment strategy and, 101e-8-9, 425  
 viruses in, 101e-7
- Cancer Genome Atlas, 101e-8
- CancerNet, 471
- Cancer prevention, 17, 475. *See also specific cancers*  
 chemoprevention, 476-478  
 diet modification, 476  
 education and healthful habits, 475-476  
 energy balance, 476  
 physical activity, 476  
 smoking cessation, 475-476  
 sun avoidance, 476  
 surgical methods, 103e-3, 479  
 vaccines and, 478-479
- Cancer screening, 27, 479. *See also specific cancers*  
 accuracy of, 479, 479t  
 assessment of tests for, 480  
 biases of tests for, 479-480  
 recommendations for asymptomatic normal-risk subjects, 481t  
 risks from, 480
- Cancer stem cells, 102e-11, 102e-12f, 103e-2, 508
- Cancer surgery, 103e-3  
 curative, 103e-3  
 diagnostic, 103e-3  
 late complications of, 620, 620t  
 palliative, 103e-3  
 preventive, 103e-3, 479
- Cancer syndromes, familial, 101e-6-7, 101e-6t, 101e-8f, 450t
- Cancrum oris (noma), 236, 487, 1097
- Candesartan, 1512t, 1624t, 2594t
- Candida* spp.  
 adherence of, 145e-2t, 145e-3  
 antifungal susceptibility testing of, 150e-8  
 characteristics of, 1342  
 epidemiology of, 1342  
 laboratory identification of, 150e-8, 1330  
 tissue invasion by, 145e-8
- Candida* spp. infections, 1342  
 in burn-wounds, 166e-1  
 in cancer patient, 486, 486t, 487-488, 489  
 catheter-related bloodstream, 98e-7, 915  
 in diabetes mellitus, 2429  
 diagnosis of, 341, 1343-1344  
 disseminated/deeply invasive, 1343f  
 brain parenchyma, 441e-8f  
 chronic meningitis, 908t  
 endocarditis, 817t, 824  
 gastrointestinal, 488, 850  
 liver abscess, 850  
 in newborn, 441e-8f  
 ocular, 1343, 1343f, 1345  
 osteomyelitis, 839  
 renal abscess, 851  
 risk factors for, 1342, 1342t  
 skin manifestations of, 25e-10f, 135, 1343, 1343f  
 treatment of, 1344-1345, 1344t  
 urinary tract, 914  
 epidemiology of, 1342
- esophageal  
 complications of, 1910  
 diagnosis of, 1256f, 1896f, 1909f  
 in HIV infection, 1256, 1909  
 treatment of, 1344t, 1910
- etiology of, 350, 350t  
 in HIV infection, 1253t  
 in immunocompromised patient, 351  
 joint, 836  
 mucocutaneous, 350  
 chronic, 1343, 2110-2111, 2345, 2346t  
 clinical features of, 1342  
 appearance, 350t, 351  
 color, 351  
 distribution, 341t  
 intertriginous, 351  
 perianal, 1343  
 prevention of, 423  
 treatment of, 350t, 351, 1344t
- oropharyngeal. *See* Thrush
- pathogenesis of, 1342
- prophylaxis for, 1253t, 1345  
 in transplant recipient, 920
- urinary, 868
- vulvovaginal  
 clinical features of, 873t, 875, 1342  
 diagnosis of, 873t, 875  
 in HIV infection, 1259  
 in systemic illness, 873  
 treatment of, 873t, 875, 1344t
- Candidate genes, 441
- Candidatus* Neoehrlichia mikurensis, 1160
- Candiru virus, 1309t
- CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature), 2215
- Cane toad (*Bufo marinus*), 310
- Cangrelor, 749
- Cannabinoid(s), 260t, 261, 469e-2. *See also* Marijuana
- Cannabinoid hyperemesis syndrome, 259
- Cantagalo, 220e-1t, 220e-2
- Cantharidin, 2750
- CAPD. *See* Continuous ambulatory peritoneal dialysis (CAPD)
- Capecitabine  
 action of, 103e-11t  
 adverse effects of, 103e-11t, 574  
 for breast cancer, 531  
 for colorectal cancer, 543  
 for gastric cancer, 535  
 genetic variations in response to, 39t  
 for pancreatic cancer, 557, 557t  
 for pNETS, 574
- Capgras' syndrome, 172, 2599
- Capillaria philippinensis*/capillariasis, 245e-3t, 765t, 1417
- Capillaries. *See* Blood vessels
- Capillaritis, 367
- Capillary leak syndrome, 46, 265e-1
- Capillary telangiectasias, 2586
- Capitulation, 15e-2, 21
- Caplan's syndrome, 1690, 2138
- Capnocytophaga* spp. infections  
 in cancer patient, 484, 484t  
 clinical features of, 183e-2-3, 782  
 complications of, 782, 1755  
 in dog-bite wound, 167e-1, 183e-3  
 etiology of, 782  
 treatment of, 167e-3, 167e-3t, 183e-2t, 183e-3
- Capreomycin, 205e-6, 1115
- CAPS (cryopyrin-associated periodic syndromes), 141, 2213t, 2215
- Capsaicin, 2232t, 2682t
- Capsid, viral, 214e-1
- Capsular polysaccharide complex (CPC), 849
- Capsule endoscopy  
 in celiac sprue, 1897f  
 in Crohn's disease, 1954, 1954f  
 in gastrointestinal bleeding, 279  
 indications for, 1878, 1879t  
 of jejunal vascular ectasia, 1883f  
 small-bowel, 1881, 1883f
- Capsulitis, adhesive, 2249
- Captopril  
 adverse effects of, 371, 380, 727t  
 for heart failure, 1511-1512, 1512t  
 for hypertension, 1624t  
 for hypertensive emergencies, 1627  
 for pulmonary edema, 1761f
- Captopril renography, 1628, 1628t
- Caput medusae, 286, 1992
- CAR (chimeric antigen receptor), 91e-4
- Caraparú virus, 1309t
- Carate. *See* Pinta
- Carbamazepine  
 for acroparesthesia, 432e-1  
 adverse effects of, 2646  
 cholestasis, 2023  
 common, 2718t  
 cross-sensitivity and, 385  
 cutaneous, 353, 361  
 fever, 138  
 genetic considerations in, 378  
 hair loss, 380  
 hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)  
 liver dysfunction, 2682t  
 lupus syndrome, 2218t  
 nail disorders, 380  
 neurologic, 2553t, 2682t  
 obesity, 2392  
 rare, 2718t  
 systemic, 2553t  
 thrombocytopenia, 727t  
 for bipolar disorder, 2718, 2718t  
 for chorea, 2153  
 contraindications to, 2552  
 drug interactions of, 42t, 205e-3, 246e-3t, 2553t  
 for epilepsy, 2552, 2553t  
 genetic variations in response to, 38, 39t  
 for neuromyotonia, 619  
 for neuropathy, 2682t  
 overdose/poisoning with, 473e-10t, 473e-13t, 2764t  
 for pain, 61, 91t, 94, 2672  
 for paroxysmal symptoms in MS, 2672  
 pharmacology of, 2553t, 2718t  
 for SUNCT/SUNA prevention, 2596  
 therapeutic monitoring of, 2764t  
 for trigeminal neuralgia, 2646
- Carbamoylphosphate synthase-1 deficiency, 434e-3t
- Carbapenem(s)  
 action of, 930, 931t  
 for anaerobic bacterial infections, 1101, 1101t  
 drug interactions of, 939t  
 for gram-negative bacterial infections, 1026-1027  
 indications for, 941  
 for multidrug-resistant TB, 205e-7  
 resistance to, 941  
 in *Acinetobacter*, 1037  
 in anaerobic bacteria, 1101  
 detection of, 769t, 774  
 in gram-negative bacteria, 1027  
 mechanisms of, 931t, 933  
 for staphylococcal infections, 961
- Carbapenemases, 933, 1026, 1027
- Carbenicillin, 306, 322
- Carbenoxolone, 64e-8
- Carbidopa/levodopa, 2614, 2616t
- Carbimazole, 354, 2199, 2296
- Carbinolamine dehydratase deficiency, 434e-2t
- Carbohydrate(s)  
 digestion and absorption of, 1937, 1937t  
 disorders of metabolism of  
 fructose metabolism disorders, 433e-1f, 433e-3t, 433e-5  
 galactose metabolism disorders, 433e-1f, 433e-3t, 433e-5  
 glycogen storage diseases. *See* Glycogen storage diseases  
 high intake of, lipoprotein disorders and, 2438  
 malabsorption of, 269  
 metabolism of, 433e-1, 433e-1f  
 requirement for, 95e-1  
 in specialized nutritional support formulas, 98e-5
- Carbon dioxide (CO<sub>2</sub>), 151e-1, 151e-2f, 151e-2t